Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study
- PMID: 36816152
- PMCID: PMC9931533
- DOI: 10.1002/bco2.204
Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study
Keywords: biochemical marker; bladder cancer; cotinine; cystectomy; muscle invasive bladder cancer; neoadjuvant chemotherapy; platinum‐based chemotherapy; salivary cotinine; smoking; treatment efficacy.
Conflict of interest statement
Dr. Mamtani reported receiving honoraria from Flatiron Health and research funding from Merck. He also served in an advisory role for Genetech/Roche and Seattle Genetics/Astellas. No other disclosures were reported.
References
-
- Cacciamani GE, Ghodoussipour S, Mari A, Gill KS, Desai M, Artibani W, et al. Association between smoking exposure, neoadjuvant chemotherapy response and survival outcomes following radical cystectomy: Systematic review and meta‐analysis. J Urol. 2020;204(4):649–60. 10.1097/JU.0000000000000813 - DOI - PubMed
-
- Sharma P, Sane N, Anand SD, Marimutthu P, Benegal V. Assessment of cotinine in urine and saliva of smokers, passive smokers, and nonsmokers: Method validation using liquid chromatography and mass spectrometry. Indian J Psychiatry. 2019;61(3):270–6. 10.4103/psychiatry.IndianJPsychiatry_61_18 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources